Copyright
©The Author(s) 2023.
World J Gastroenterol. May 28, 2023; 29(20): 3066-3083
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3066
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3066
Ref. | Study design | Group (n) | DBD/DCD | HOPE duration (median) | Definition of ITBL | Follow up | ITBL-intervention | ITBL-control | ||
DCD | DBD | DCD | DBD | |||||||
Schlegel et al[61], 2023 | RCT | HOPE (85) vs SCS (85) | DBD | 95.5 min | NR | 12 mo | NA | 1/85 (1.2%) | NA | 3/85 (3.5%) |
Ravaioli et al[56], 2022 | RCT | HOPE (66) vs SCS (69) | DBD | 145 min | Nonspecifically provided: Biliary strictures; Biliary others | 12 mo | NA | 5/55 (9%) | NA | 6/55 (11%) |
van Rijn et al[52], 2021 | RCT | D-HOPE (78) vs SCS (78) | DCD | 132 min | Symptomatic NAS diagnosed with the use of 6-mo cholangiography in the presence of a patent HA | 6 mo | 5/78 (6%) | NA | 14/78 (18%) | NA |
Czigany et al[57], 2021 | RCT | HOPE (23) vs SCS (23) | DBD | 145 min | Biliary complications (clinical; radiological) | 12 mo | NA | 4/23 (17%) | NA | 6/23 (26%) |
Patrono et al[60], 2022 | Cohort | D-HOPE (121) vs SCS (723) | DBD | 138 min | Biliary complications 3-mo cholangiography if clinically indicated | Median 21.6 (D-HOPE) and 51.1 (SCS) mo | NA | 5/121 (4%) | NA | 35/723 (5%) |
Rayar et al[58], 2021 | Cohort | HOPE (25) vs SCS (69) | DBD | 117 min | NR | 12 mo | NA | 0/25 (0%) | NA | 1/69 (1.5%)1 |
Muller et al[37], 2020 | Cohort | NRP (132) vs HOPE (93) | DCD | 132 min | NAS was defined as strictures with or without HA thrombosis or arterial complications. | Median 20 (NRP) 28 mo (HOPE) mo | 2/32 (6.3%) | NA | 4/32 (12.5%) | NA |
Ravaioli et al[59], 2020 | Cohort | HOPE (10) vs SCS (30) | DBD | 132 min | NR | 12 mo | NA | NP | NA | NP |
Schlegel et al[55], 2019 | Cohort | HOPE (50) vs SCS DBD (50) vs SCS DCD (50) | Both | 120 min | Ischemic cholangiopathy defined radiologically, as intrahepatic or hilar BS and dilatations with patent HA | 5 yr | 4/50 (8%) | NA | 11/50 (22%) | 1/50 (2%) |
van Rijn et al[51], 2017 | Cohort | D-HOPE (10) vs SCS (20) | DCD | 126 min | NAS was defined as bile duct stenosis in the biliary tree as detected by ERCP or MRCP with clinical signs of cholestasis and/or cholangitis in the presence of a patent HA | 12 mo | 1/10 (10%) | NA | 9/20 (45%)2 | NA |
- Citation: Durán M, Calleja R, Hann A, Clarke G, Ciria R, Nutu A, Sanabria-Mateos R, Ayllón MD, López-Cillero P, Mergental H, Briceño J, Perera MTPR. Machine perfusion and the prevention of ischemic type biliary lesions following liver transplant: What is the evidence? World J Gastroenterol 2023; 29(20): 3066-3083
- URL: https://www.wjgnet.com/1007-9327/full/v29/i20/3066.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i20.3066